establish if factors such as gender, serum ACE level and radiographic stage influence sensitivity thresholds. Methods Twenty-four patients with sarcoidosis (mean (SEM) age 49 (2) years, 63% female) were recruited from a specialist clinic and underwent assessment of CRS by a single-breath inhalation capsaicin cough challenge test to determine the concentration causing 5 or more coughs (C 5 ). Anthropometric data, spirometry, serum ACE levels and radiographic stage were recorded. The effects of gender, age, ethnicity, radiographic stage and serum ACE levels on cough reflex sensitivity were investigated. CRS data of 134 healthy subjects from a previous study were used for comparison (Prudon B et al, Chest 2005; 127:550) . Results CRS was heightened in patients with sarcoidosis compared to healthy subjects (geometric mean (logSD) C 5 13.5 (0.5) vs 158.5 (0.6) mmol/l, p<0.001). Female patients had a more sensitive cough reflex compared to males (geometric mean (logSD) C 5 8.1 (0.5) vs 31.8 (0.5) mmol/l, p¼0.007). Seven patients did not complain of cough; there was no difference in CRS compared to patients who reported cough (p¼0.68). There was no difference in CRS between patients of Afro-Caribbean origin compared to non-Afro-Caribbean patients (geometric mean (logSD) C 5 10.1 (0.5) vs 24.3 (0.6) mmol/l, p¼0.09). Serum ACE levels correlated significantly with logC 5 (r¼0.74, p<0.001), with lower ACE levels being associated with a more sensitive cough reflex. There was no relationship between logC 5 and age (r¼À0.40, p¼0.054) or radiographic stage (p¼0.83). Conclusions Patients with sarcoidosis have a heightened CRS. This was increased to a greater degree in females, but age or radiographic stage had no effect. We report for the first time a link between serum ACE levels and cough reflex sensitivity, and hypothesise that low concentrations of serum ACE lead to increased airway tussigenic mediators such as bradykinin. Further studies should investigate whether cough receptors such as TRPV1 are upregulated in sarcoidosis. Background Idiopathic pulmonary fibrosis is a fatal condition with limited treatment options; however in a previous small study cotrimoxazole has been shown to be beneficial. Methods In a double-blind, multi-centre study, 181 patients with usual interstitial pneumonia (n¼166) or fibrotic non-specific interstitial pneumonia (n¼15) were randomised to receive co-trimoxazole 960 mg twice daily or placebo for 12 months in addition to their usual care. Measurements were made of forced vital capacity (FVC), total lung capacity, total lung diffusing capacity of carbon monoxide, Medical Research Council dyspnoea score, St George's Respiratory Questionnaire and quality adjusted life years (QALYs). All cause mortality, costs and adverse events were recorded. Results Co-trimoxazole had no effect on FVC or other measures of lung function. However in the per-protocol analysis, co-trimoxazole resulted in a significant reduction in mortality (HR of 0.2 (0.06, 0.78)), significant improvements in the symptom domain of St George's Respiratory Questionnaire (mean difference À5.30 (À11.99, 1.40) units) and QALYs gained (mean difference 0.12 (0.01, 0.22) QALYs), and a reduction in the percentage of patients requiring an increase in oxygen therapy (OR 0.05 (0.00, 0.61)) compared to placebo. Furthermore, the use of co-trimoxazole reduced respiratory tract infections. The incremental cost per QALY gained was £21 391 (52.74% probability of being below £30 000; intention to treat analysis, UK societal perspective).
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